Cantargia has submitted a phase I clinical trial application

Cantargia today announced that an application has been submitted to start the phase I clinical trial for the IL1RAP-binding antibody CAN10, in development for treatment of systemic sclerosis and... | April 20, 2023

Related Keywords

, Cantargia Ab Publ Stock Exchange , News , Information , Press Release , Cantargia , Oday , Nnounced , Hat , N , Application , Gas , Teen , Ubmitted , O , Start , The , Hase , Linical , Trial , Or , Ntibody , Development , Treatment , F , Systemic , Clerosis Canta Se0006371126 ,